Viking Therapeutics Inc (VKTX)
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells.
VKTX SEC Filing Email Alerts Service
Company Name: |
Viking Therapeutics Inc |
Website: |
www.vikingtherapeutics.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding VKTX: |
23 |
Total Market Value Held by ETFs: |
$791.78M |
Total Market Capitalization: |
$6.53B |
% of Market Cap. Held by ETFs: |
12.13% |
|
|
April 26, 2024 4:02 AM Eastern
Strong Buy (3.90 out of 4)
75th percentile
|
|